Nuvalent (NUVL) announced that the first patient has been dosed in Alkazar, the company’s global Phase 3 randomized, controlled trial evaluating neladalkib for TKI-naive patients with advanced ALK-positive non-small cell lung cancer, versus Alecensa, a front-line standard of care.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent’s Promising Biotech Advancements: Buy Rating Backed by Strong Clinical Results
- Nuvalent assigned Buy rating, $105 price target at Goldman Sachs
- Nuvalent price target raised to $112 from $105 at Baird
- Nuvalent’s Zidesamtinib: A Promising Blockbuster in the ROS1 Inhibitor Landscape
- Nuvalent price target raised to $140 from $125 at Leerink